eligibility_summary
Eligibility: Adults (>18) treated with glofitamab via Compassionate Use Program AG42296, receiving ≥1 dose between Mar 2022–Sep 2023, with ≥1 year follow-up after last dose unless deceased or lost to follow-up, and consent provided per local regulations (or attempts made per privacy rules for deceased/lost). Exclusions: none.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Study: Observational evaluation of glofitamab as salvage therapy in relapsed/refractory B‑cell non‑Hodgkin lymphoma (Italy, compassionate use). Drug/intervention: Glofitamab, a T‑cell–engaging bispecific monoclonal antibody (IgG, 2:1 format) targeting CD20 on B cells and CD3 on T cells. Mechanism of action: Bridges T cells to CD20+ malignant B cells, triggering TCR/CD3 signaling, T‑cell activation, immunologic synapse formation, and cytotoxic killing via perforin/granzyme and apoptosis, associated cytokine release. Cells/pathways targeted: CD20+ B lymphocytes, T‑cell receptor/CD3 activation and downstream cytotoxic effector pathways. Primary focus: complete response rate.